 Katja Kiseljak-Vassiliades
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenocortical Carcinoma | 11 | 2023 | 47 | 5.840 |
Why?
| | Adrenal Cortex Neoplasms | 10 | 2023 | 48 | 4.840 |
Why?
| | Adenoma | 5 | 2019 | 187 | 1.520 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 3 | 2017 | 11 | 1.420 |
Why?
| | Pituitary Neoplasms | 7 | 2019 | 156 | 1.060 |
Why?
| | Adrenal Cortex | 3 | 2020 | 32 | 0.920 |
Why?
| | Pituitary Gland | 4 | 2018 | 147 | 0.820 |
Why?
| | Disease Models, Animal | 3 | 2021 | 3498 | 0.810 |
Why?
| | Dehydroepiandrosterone | 1 | 2022 | 49 | 0.780 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 428 | 0.760 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2021 | 81 | 0.720 |
Why?
| | Androgens | 1 | 2022 | 167 | 0.710 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2020 | 181 | 0.690 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 113 | 0.650 |
Why?
| | Genes, Tumor Suppressor | 3 | 2017 | 77 | 0.640 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 193 | 0.590 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2023 | 1145 | 0.580 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 30 | 0.570 |
Why?
| | Desmosomes | 1 | 2017 | 20 | 0.570 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 24 | 0.510 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 69 | 0.500 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 660 | 0.500 |
Why?
| | Cell Line, Tumor | 9 | 2023 | 2700 | 0.480 |
Why?
| | Membrane Proteins | 2 | 2019 | 1016 | 0.480 |
Why?
| | Acromegaly | 1 | 2014 | 12 | 0.470 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 695 | 0.470 |
Why?
| | Cadherins | 1 | 2015 | 175 | 0.460 |
Why?
| | Human Growth Hormone | 1 | 2014 | 38 | 0.460 |
Why?
| | Neurosurgical Procedures | 2 | 2018 | 150 | 0.460 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 1875 | 0.420 |
Why?
| | Apoptosis | 6 | 2021 | 2349 | 0.320 |
Why?
| | Cell Proliferation | 7 | 2023 | 2173 | 0.320 |
Why?
| | Tumor Cells, Cultured | 3 | 2021 | 845 | 0.310 |
Why?
| | Mice, Nude | 2 | 2020 | 628 | 0.300 |
Why?
| | Humans | 30 | 2023 | 114045 | 0.300 |
Why?
| | Biomarkers, Tumor | 3 | 2021 | 1032 | 0.290 |
Why?
| | Prognosis | 3 | 2022 | 3315 | 0.270 |
Why?
| | Immunotherapy | 2 | 2021 | 473 | 0.270 |
Why?
| | Middle Aged | 9 | 2023 | 26605 | 0.220 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 146 | 0.210 |
Why?
| | Mice | 7 | 2021 | 14843 | 0.200 |
Why?
| | Luteinizing Hormone | 1 | 2023 | 169 | 0.200 |
Why?
| | Anorexia | 1 | 2022 | 18 | 0.200 |
Why?
| | Animals | 11 | 2023 | 31565 | 0.200 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 549 | 0.190 |
Why?
| | Aldosterone | 2 | 2019 | 42 | 0.190 |
Why?
| | Hormone Replacement Therapy | 1 | 2022 | 76 | 0.190 |
Why?
| | Mitotane | 1 | 2020 | 6 | 0.180 |
Why?
| | Aurora Kinase A | 1 | 2021 | 51 | 0.180 |
Why?
| | Phthalazines | 1 | 2021 | 38 | 0.180 |
Why?
| | Heterografts | 1 | 2021 | 117 | 0.180 |
Why?
| | Pheochromocytoma | 1 | 2021 | 54 | 0.180 |
Why?
| | Paraganglioma | 1 | 2021 | 46 | 0.180 |
Why?
| | Adrenal Gland Diseases | 1 | 2020 | 6 | 0.170 |
Why?
| | Benzamides | 1 | 2021 | 168 | 0.170 |
Why?
| | Neuroendocrine Tumors | 1 | 2021 | 85 | 0.170 |
Why?
| | Indolizines | 1 | 2019 | 3 | 0.170 |
Why?
| | Forkhead Box Protein M1 | 1 | 2019 | 5 | 0.170 |
Why?
| | Immune System | 1 | 2021 | 171 | 0.170 |
Why?
| | Estrogens | 1 | 2022 | 312 | 0.170 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 179 | 0.160 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 84 | 0.160 |
Why?
| | Liver Neoplasms | 1 | 2023 | 504 | 0.160 |
Why?
| | Quinoxalines | 1 | 2019 | 60 | 0.160 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 111 | 0.160 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2018 | 9 | 0.160 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 149 | 0.160 |
Why?
| | Gonadal Steroid Hormones | 1 | 2020 | 123 | 0.160 |
Why?
| | Trans-Activators | 1 | 2021 | 366 | 0.160 |
Why?
| | Lamin Type B | 1 | 2018 | 5 | 0.150 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 5 | 0.150 |
Why?
| | Gadolinium | 1 | 2019 | 73 | 0.150 |
Why?
| | Female | 9 | 2023 | 59324 | 0.150 |
Why?
| | Signal Transduction | 4 | 2023 | 4501 | 0.150 |
Why?
| | Naphthyridines | 1 | 2018 | 16 | 0.150 |
Why?
| | Adult | 8 | 2023 | 30375 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 2 | 2015 | 784 | 0.150 |
Why?
| | Carcinogenesis | 1 | 2019 | 175 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2020 | 307 | 0.150 |
Why?
| | Calcium-Binding Proteins | 1 | 2019 | 205 | 0.150 |
Why?
| | Mutation | 3 | 2021 | 3338 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 152 | 0.150 |
Why?
| | Immunoblotting | 1 | 2018 | 282 | 0.150 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 534 | 0.140 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 314 | 0.140 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1144 | 0.140 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 131 | 0.140 |
Why?
| | Microarray Analysis | 1 | 2017 | 118 | 0.140 |
Why?
| | Colorectal Neoplasms | 1 | 2023 | 592 | 0.140 |
Why?
| | Genomics | 1 | 2021 | 631 | 0.140 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1624 | 0.140 |
Why?
| | Contrast Media | 1 | 2019 | 347 | 0.130 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2015 | 13 | 0.130 |
Why?
| | Transcriptome | 2 | 2021 | 723 | 0.130 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 66 | 0.130 |
Why?
| | Gonadotrophs | 2 | 2015 | 21 | 0.120 |
Why?
| | Phosphatidylcholines | 1 | 2016 | 132 | 0.120 |
Why?
| | Phosphorylation | 1 | 2019 | 1558 | 0.120 |
Why?
| | Testosterone | 2 | 2023 | 341 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1518 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 607 | 0.120 |
Why?
| | Prospective Studies | 2 | 2023 | 6195 | 0.110 |
Why?
| | Cell Survival | 4 | 2021 | 1014 | 0.110 |
Why?
| | Veterans | 1 | 2023 | 1248 | 0.100 |
Why?
| | Hypogonadism | 1 | 2012 | 75 | 0.100 |
Why?
| | Quality of Life | 1 | 2022 | 2343 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 79 | 0.090 |
Why?
| | Models, Molecular | 1 | 2015 | 1368 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2018 | 12521 | 0.090 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 438 | 0.090 |
Why?
| | Glycoproteins | 1 | 2012 | 304 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 283 | 0.080 |
Why?
| | Male | 8 | 2023 | 55396 | 0.080 |
Why?
| | Pyrazoles | 1 | 2012 | 361 | 0.080 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2010 | 189 | 0.080 |
Why?
| | Reproduction | 1 | 2010 | 176 | 0.080 |
Why?
| | Pyridines | 1 | 2012 | 419 | 0.080 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1162 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2016 | 1072 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3039 | 0.070 |
Why?
| | Models, Biological | 2 | 2012 | 1611 | 0.070 |
Why?
| | Neoplasms | 1 | 2021 | 2086 | 0.070 |
Why?
| | Age Factors | 1 | 2014 | 2885 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1468 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 742 | 0.070 |
Why?
| | Aged | 4 | 2023 | 18969 | 0.070 |
Why?
| | Insulin | 1 | 2016 | 2080 | 0.070 |
Why?
| | Carcinoma, Papillary | 1 | 2006 | 74 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 155 | 0.070 |
Why?
| | Cell Movement | 1 | 2010 | 863 | 0.070 |
Why?
| | Gene Silencing | 1 | 2006 | 171 | 0.060 |
Why?
| | Exercise | 1 | 2016 | 1642 | 0.060 |
Why?
| | Up-Regulation | 2 | 2021 | 802 | 0.060 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2006 | 191 | 0.060 |
Why?
| | United States | 1 | 2020 | 12137 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 959 | 0.060 |
Why?
| | Floxuridine | 1 | 2023 | 5 | 0.050 |
Why?
| | Thyroid Neoplasms | 1 | 2006 | 271 | 0.050 |
Why?
| | Triamcinolone Acetonide | 1 | 2023 | 27 | 0.050 |
Why?
| | Hepatic Artery | 1 | 2023 | 49 | 0.050 |
Why?
| | Neurons | 1 | 2010 | 1277 | 0.050 |
Why?
| | DNA Methylation | 1 | 2006 | 493 | 0.050 |
Why?
| | Stress, Physiological | 2 | 2015 | 379 | 0.050 |
Why?
| | Follicle Stimulating Hormone | 1 | 2023 | 216 | 0.050 |
Why?
| | Cellular Senescence | 1 | 2023 | 151 | 0.050 |
Why?
| | Aurora Kinase B | 1 | 2021 | 7 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 62 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 79 | 0.050 |
Why?
| | Drug Synergism | 1 | 2021 | 315 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 312 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 493 | 0.040 |
Why?
| | Zebrafish | 1 | 2023 | 413 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 552 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 108 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1360 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 388 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 322 | 0.040 |
Why?
| | Remission Induction | 1 | 2018 | 233 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 850 | 0.040 |
Why?
| | Postoperative Period | 1 | 2018 | 288 | 0.040 |
Why?
| | Cell Line | 2 | 2012 | 2629 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 519 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2015 | 101 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2015 | 135 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 33 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 51 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 2562 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2016 | 343 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 95 | 0.030 |
Why?
| | Gene Amplification | 1 | 2015 | 95 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 153 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 249 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 221 | 0.030 |
Why?
| | Indoles | 1 | 2015 | 300 | 0.030 |
Why?
| | Aging | 1 | 2023 | 1611 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 2784 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2016 | 587 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 250 | 0.030 |
Why?
| | Athletes | 1 | 2016 | 328 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 397 | 0.030 |
Why?
| | Binding Sites | 1 | 2015 | 1166 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 796 | 0.030 |
Why?
| | Sulfonamides | 1 | 2015 | 444 | 0.030 |
Why?
| | G2 Phase | 1 | 2012 | 31 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 118 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 109 | 0.020 |
Why?
| | Cytoplasm | 1 | 2012 | 255 | 0.020 |
Why?
| | Genes, p53 | 1 | 2011 | 61 | 0.020 |
Why?
| | Protein Binding | 1 | 2015 | 1888 | 0.020 |
Why?
| | Cell Division | 1 | 2012 | 754 | 0.020 |
Why?
| | Olfactory Pathways | 1 | 2010 | 56 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 521 | 0.020 |
Why?
| | Hypoxia | 1 | 2015 | 956 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 990 | 0.020 |
Why?
| | Neurogenesis | 1 | 2010 | 102 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 351 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1131 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4595 | 0.020 |
Why?
| | Blood Glucose | 1 | 2016 | 1827 | 0.020 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2006 | 20 | 0.020 |
Why?
| | Tissue Inhibitor of Metalloproteinase-3 | 1 | 2006 | 7 | 0.020 |
Why?
| | Death-Associated Protein Kinases | 1 | 2006 | 10 | 0.020 |
Why?
| | Receptors, Retinoic Acid | 1 | 2006 | 49 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 170 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2006 | 170 | 0.020 |
Why?
| | Cation Transport Proteins | 1 | 2006 | 123 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 9049 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 924 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 10444 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2087 | 0.010 |
Why?
| | Adolescent | 1 | 2018 | 17800 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 6306 | 0.010 |
Why?
| | Disease Progression | 1 | 2006 | 2371 | 0.010 |
Why?
|
|
Kiseljak-Vassiliades's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|